About us
About Pharmetheus
History
Mission & Values
Leadership
Scientific advisors
Our team
Social impact (CSR)
Science & Services
Contexts of use
Trial design and analysis
Program strategies and efficiences
Special/specific populations
Special considerations
Regulatory interactions
Pharmetheus Platforms
Model-Informed Drug Development
PBPK & PBBM
Pharmacometrics
QSP
Solutions
Milestone Analysis
Embedded Scientists
Expert Advice
Scientific Publication
Specific services
Model-Informed Bioequivalence & Biosimilarity
Accelerated submission
Concentration-QTc (C-QTc) modeling
Data-driven strategies for pediatric success
Training workshops
Publications
Case studies
Articles
Careers
Working with us
Open positions
Employee stories
Events
News
Contact us
Home
Publications
Population PK and PASI Exposure-Response Modelling for Certolizumab Pegol in Patients with Chronic Plaque Psoriasis
Population PK and PASI Exposure-Response Modelling for Certolizumab Pegol in Patients with Chronic Plaque Psoriasis
Immunology
Pharmacometrics
PAGE 28 (2019) Abstr 9118.
Sarr C, Magnusson MO, Vajjah P, Zamacona M